Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Shattuck Labs, Inc.STTK · Entity 5224 | Chief Financial Officer | May 12, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Shattuck Labs, Inc.
Report date May 12, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 292,251 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 64,027 · Balance 292,251 |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 | Direct | 0 |
Reported balance
After 2026-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-12 · Exercise / conversion · Disposed 64,027 · Balance 0 F1: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F2: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
F2: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 15, 2026 00:10 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionWarrants (Right to Buy) · Derivative | 64,027 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001193125-26-224692 · ownership.xml · derivative · entry 2 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,027 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F2 · derivative.exercise_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. F2 · derivative.expiration_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. Read SEC document |
| May 12, 2026 Filed May 15, 2026 00:10 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 64,027 | $1.08 | $69,443.68 |
DisclosureSEC source: 0001193125-26-224692 · ownership.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,251 Read SEC document |
| January 25, 2026 Filed Jan 27, 2026 21:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 2,589 | $4.15 | $10,744.35 |
DisclosureSEC source: 0001193125-26-024393 · ownership.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,224 Read SEC document |
| January 10, 2026 Filed Jan 13, 2026 21:42 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 549,800 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001193125-26-011828 · ownership.xml · derivative · entry 2 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 549,800 Underlying: Common Stock · 549,800 shares Expires 2036-01-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 549,800 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2026 Filed Jan 13, 2026 21:42 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 6,660 | $4.75 | $31,635.00 |
DisclosureSEC source: 0001193125-26-011828 · ownership.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,813 Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 10:30 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantWarrants (Right to Buy) · Derivative | 64,027 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001193125-25-189088 · ownership.xml · derivative · entry 2 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,027 Underlying: Common Stock · 64,027 shares Expires not disclosed F1 · kind: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F2 · derivative.exercise_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. F2 · derivative.expiration_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 10:30 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 64,027 | $0.87 | $55,556.23 |
DisclosureSEC source: 0001193125-25-189088 · ownership.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,473 F1 · kind: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. Read SEC document |
| January 28, 2025 Filed Jan 28, 2025 22:56 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 214,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0000950170-25-009991 · ownership.xml · derivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,000 Underlying: Common Stock · 214,000 shares Expires 2035-01-28 F1 · derivative.exercise_date: This option represents a right to purchase a total of 214,000 shares of the Issuer's common stock, one quarter of which will vest on January 28, 2026, with the remaining three quarters vesting in equal monthly installments through January 28, 2029, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2024 Filed Jan 16, 2024 21:35 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 113,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0000950170-24-004656 · ownership.xml · derivative · entry 4 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock · 113,000 shares Expires 2034-01-10 F2 · derivative.exercise_date: This option represents a right to purchase a total of 113,000 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2025, with the remaining three quarters vesting in equal monthly installments through January 10, 2028, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2024 Filed Jan 16, 2024 21:35 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 25,000 | $10.00 | $250,000.00 |
DisclosureSEC source: 0000950170-24-004656 · ownership.xml · nonDerivative · entry 3 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,446 Read SEC document |
| January 10, 2024 Filed Jan 16, 2024 21:35 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 2,470 | $10.09 | $24,922.30 |
DisclosureSEC source: 0000950170-24-004656 · ownership.xml · nonDerivative · entry 2 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,446 Read SEC document |
| January 10, 2024 Filed Jan 16, 2024 21:35 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 56,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-004656 · ownership.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,916 F1 · shares: Consists of 56,500 restricted stock units, which will vest in four equal annual installments beginning on January 10, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 23:13 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 69,850 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0000899243-23-002890 · doc4.xml · derivative · entry 2 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,850 Underlying: Common Stock · 69,850 shares Expires 2033-01-25 F2 · derivative.exercise_date: This option represents a right to purchase a total of 69,850 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 23:13 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 34,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002890 · doc4.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,416 F1 · shares: Consists of 34,925 restricted stock units, which will vest in four equal annual installments beginning on January 25, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 23:43 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 66,650 | $0.00 Strike: $7.43 | $0.00 |
DisclosureSEC source: 0000899243-22-001794 · doc4.xml · derivative · entry 2 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,650 Underlying: Common Stock · 66,650 shares Expires 2032-01-10 F2 · derivative.exercise_date: This option represented a right to purchase a total of 66,650 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2023, with the remaining three quarters vesting in equal monthly installments through January 10, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 23:43 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 33,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001794 · doc4.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,491 F1 · shares: Consists of 33,325 restricted stock units, which will vest in four equal annual installments beginning on January 10, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 11:10 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0000899243-21-044264 · doc4.xml · derivative · entry 2 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,705 Underlying: Common Stock · 20,000 shares Expires 2028-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents a right to purchase a total of 63,705 shares of the Issuer's common stock, one quarter of which vested on September 18, 2019, with the remaining shares vesting in equal monthly installments through May 15, 2022, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 11:10 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 20,000 | $2.95 | $59,000.00 |
DisclosureSEC source: 0000899243-21-044264 · doc4.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This option represents a right to purchase a total of 63,705 shares of the Issuer's common stock, one quarter of which vested on September 18, 2019, with the remaining shares vesting in equal monthly installments through May 15, 2022, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 21:00 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,203 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0000899243-21-032550 · doc4.xml · derivative · entry 2 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,203 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represented a right to purchase a total of 17,700 shares of the Issuer's common stock and has vested in full. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 21:00 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 2,203 | $0.01 | $22.03 |
DisclosureSEC source: 0000899243-21-032550 · doc4.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This option represented a right to purchase a total of 17,700 shares of the Issuer's common stock and has vested in full. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 21:07 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 2,000 | $22.13 | $44,263.20 |
DisclosureSEC source: 0000899243-21-028674 · doc4.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,963 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $21.315 to $22.78. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 23:27 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 2,000 | $27.53 | $55,050.60 |
DisclosureSEC source: 0000899243-21-024264 · doc4.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,963 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $27.08 to $28.55. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 17, 2021 Filed May 18, 2021 01:08 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 2,000 | $26.27 | $52,542.40 |
DisclosureSEC source: 0000899243-21-019687 · doc4.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,963 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $25.91 to $26.61. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2021 Filed May 13, 2021 00:38 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,860 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0000899243-21-019312 · doc4.xml · derivative · entry 2 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,203 Underlying: Common Stock · 8,860 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents a right to purchase a total of 17,700 shares of the Issuer's common stock and will vest in equal monthly installments through May 22, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 12, 2021 Filed May 13, 2021 00:38 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 8,860 | $0.01 | $88.60 |
DisclosureSEC source: 0000899243-21-019312 · doc4.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 21:00 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 20,000 | $35.00 | $700,000.00 |
DisclosureSEC source: 0000899243-21-017648 · doc4.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,103 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.00 to $35.18. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 22:16 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 24,000 | $30.74 | $737,760.00 |
DisclosureSEC source: 0000899243-21-016249 · doc4.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,103 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $29.72 to $33.03. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:47 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 14,608 | $0.00 Strike: $53.02 | $0.00 |
DisclosureSEC source: 0000899243-20-035209 · doc4.xml · derivative · entry 3 Neill Andrew R · CIK 0001827204 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,608 Underlying: Common Stock · 14,608 shares Expires 2030-12-22 F2 · derivative.exercise_date: This option represents a right to purchase a total of 14,608 shares of the Issuer's common stock, one quarter of which will vest on December 22, 2021, with the remaining three quarters vesting in equal monthly installments through December 22, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:47 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,426 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0000899243-20-035209 · doc4.xml · derivative · entry 2 Neill Andrew R · CIK 0001827204 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,063 Underlying: Common Stock · 4,426 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents a right to purchase a total of 17,700 shares of the Issuer's common stock and will vest in equal monthly installments through May 22, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:47 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 4,426 | $0.01 | $44.26 |
DisclosureSEC source: 0000899243-20-035209 · doc4.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 21:30 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,211 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0000899243-20-030627 · doc4.xml · derivative · entry 2 Neill Andrew R · CIK 0001827204 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,489 Underlying: Common Stock · 2,211 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents a right to purchase a total of 17,700 shares of the Issuer's common stock and will vest in equal monthly installments through May 22, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 21:30 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 2,211 | $0.01 | $22.11 |
DisclosureSEC source: 0000899243-20-030627 · doc4.xml · nonDerivative · entry 1 Neill Andrew R · CIK 0001827204 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.